











(B) Effect on metastatic lung cancer









Research Spotlight / News and Analysis

Emergence of EPR Effect Theory and Development of Clinical Applications for Cancer Therapy

Hiroshi Maeda

Institute of Drug Delivery Science, Sojo University, Kumamoto, Japan

Keywords:

Tumor uptake, nanoparticle, antimetastasis, lymphotropism, vascular permeability, tumor selective delivery, enhancement of EPR effect

Historical background of the enhanced permeability and retention (EPR) effect

This is a personal recollection of how we discovered the EPR effect for tumor selective delivery of anticancer drugs. The story of the EPR effect has three components: (i) development of the macromolecular drug (poly(maleic acid-styrene)-conjugated neocarzinostatin, or SMANCS), (ii) studies of infection and inflammation and the vascular permeability mediator bradykinin (BK), and (iii) biology and pharmacology of cancer. The first component involved synthesis of macromolecular

drugs (now called nanomedicines), because drugs of low molecular weight (MW) demonstrated no EPR effect. In 1960s, we isolated antitumor protein neocarzinostatin (NCS, MW 12 kDa) from culture filtrates of *Streptomyces carzinostaticus*, and determined its characteristics, chemistry (structure), and pharmacology (1). At that time, very little was known about the pharmacology of protein drugs. These studies were the beginning of development of the polymer drug SMANCS (1).

Vascular permeability in infection and inflammation

The second component of this endeavor was related to bacterial infection: the pathogenic effect of bacterial proteases, which infecting bacteria produce. These investigations led to the discovery of the activation of the proteolytic cascade that resulted in generation of BK, which is the most potent pain-inducing endogenous peptide and facilitates extravasation of macromolecules or plasma proteins at infection sites (2). This extravasation in inflamed tissues is a common phenomenon also observed in viral (e.g., influenza virus) infections that cause pneumonia and inflammation. Our most intriguing finding was simultaneous generation of superoxide (anion) radical ($O_2^{\cdot -}$) and nitric oxide (NO) (via activation of nitric oxide synthase) (3,4). This *in vivo* reaction produced a potent tissue-damaging peroxide ($ONOO^-$) that also

activates collagenases (e.g., metalloproteinase-2) and other enzymes, which enhance vascular permeability. Just as for bacterial protease, the BK-generating cascade occurred in cancer tissues (5,6); formation of pleural and ascetic fluids in carcinomatosis also depends on generation of BK and other vascular mediators.

Another project at my department at Kumamoto University Medical School concerned cancer chemotherapy—the third component leading to discovery of the EPR effect. We investigated the accumulation of SMANCS in tumors after intravenous injection. To our surprise, its accumulation in tumors was more marked than accumulation in other normal tissues or organs (1,6-8). We therefore studied the accumulation of the most biocompatible macromolecules (e.g. albumin) in a tumor-bearing mice. Most interestingly, albumin accumulation in tumors increased progressively with time, for more than a few days (8), and its concentration in tumors was higher than its concentration in plasma at several hours after intravenous injection (1,6-8). In contrast to these macromolecules, low-MW compounds (e.g., doxorubicin) disappeared within a few hours. Uptake of macromolecules by normal tissues such as the kidney, liver, muscles, and intestine was far lower (1/10-1/30) than uptake by tumors, and the macromolecules were gradually cleared from normal tissues (via lymphatics) in a week, whereas their tumor concentration remained quite high for weeks or longer

(4,8,9). This retention was a unique feature of tumor tissue, so the word *retention* was incorporated into the term EPR effect. We continued investigating this phenomenon, in collaboration with Professors Ruth Duncan of the Univ. of Birmingham, UK and Karel Ulbrich of Inst. of Macromolecular Chemistry, Prague, Czech Republic, by using highly biocompatible synthetic polymers (HPMA, *N*-(2-hydroxypropyl)methacrylamide polymers). The results with HPMA polymers were consistent with findings with plasma proteins including, albumin, transferrin and immunoglobulin (6-8).

Lymphotropic characteristics and antimetastatic activity of nanomedicines

We investigated the tissue distribution of a small antitumor protein (NCS, 12 kDa) *in vivo* and obtained a fascinating result: when we injected NCS subcutaneously, we found a marked accumulation in regional lymph nodes (1,9-11). This finding prompted us to make NCS more lymphotropic by conjugating it with a hydrophobic polymer, styrene-co-maleic acid (SMA) polymer, to produce SMANCS. That is, we synthesized SMANCS, which accumulated in lymph nodes more than any other tissues (10).

Lymphatic metastasis is the most formidable problem in cancer treatment, but metastatic tumors, which may be seen as small tumor nodules with diameters less than 0.5 mm, do in fact exhibit the EPR effect (12). One of the advantage of lymphotropism of

such polymeric conjugates (SMANCS) was therefore effectiveness against lymphatic metastasis (1,6,10-12). It should be noted that metastatic tumor nodules are fed by blood vessels (neovasculature), not by the lymphatic system as they grow (13).

The power of the lipid formulation

SMANCS, unique in its high lipophilicity, has styrene residues that make oily formulations possible by using lipidic X-ray contrast agent [Lipiodol®]. SMANCS in Lipiodol® can be administered via tumor-feeding arteries, such as the hepatic artery for hepatoma, and can accomplish the highest effective tumor-selective targeting of drugs [tumor/blood ratio > 1000 (14)]. SMANCS in Lipiodol® yielded the most impressive regression of hepatomas, renal cell carcinomas, gallbladder and pancreatic cancers, and metastatic liver cancers (15,16). This Lipiodol® formulation has at least two advantages: it yields a clear tumor image by CT-scan (6,14-16), and one can obtain semiquantitative data about the amount of drug retained in tumors as white area in tumor.

Another advantage of the oily formulation was that oral delivery of peptide- and protein- derivatives became possible, because this formulation was stable in gastric juice and improved absorbability from the intestine more than 17-fold compared with the

aqueous formulation of SMANCS (17). This approach has unfortunately not received much attention.

Augmentation of the EPR effect and heterogeneity of the effect in cancer:

Further enhancement of drug delivery to tumor.

Cancer and inflamed tissues share many vascular mediators that cause gaps between tight endothelial cell-cell junctions to open. As discussed above, BK and NO, among others, play a major role in the EPR effect. Angiotensin-converting enzyme (ACE) can convert angiotensin I (AT-I) to AT-II and also degrade BK because they have the amino acid sequence in common. Thus, ACE degrades BK, and ACE inhibitor blocks BK-degradation (5,6). Consequently, ACE inhibitors such as enalapril cause higher local BK concentrations, with the EPR effect thus being enhanced. Similarly, NO generators such as nitroglycerin (NG) applied topically enhance the EPR effect because NO mediates the effect. NG is quickly absorbed and becomes nitrite *in vivo*, and then nitrite (NO_2^-) is reduced to NO in hypoxic tumor tissue (6,8,18). Application of NG ointment to tumor-bearing hosts resulted in a 2- to 3-fold increase in delivery of macromolecular drugs to tumors (18) and an improved clinical effect (19).

By infusing AT-II, which is a physiological vasoconstrictor, one can elevate blood

pressure (eg. from 110 to 150–160 mmHg), and selective delivery of drugs to tumors will increase via passive opening of endothelial gaps (6,16), with enhanced clinical effects (18). NG and ACE inhibitors are safe and inexpensive and will solve the problem of low or heterogeneous EPR effects in tumors (6,19).

The vascular pathology of solid tumors is variable and frequently heterogeneous, with necrotic areas having obstructed blood flow, just as in infarcted cardiac tissue. We found that an augmented EPR effect, as described above, improves tumor blood flow and hence drug delivery. Pretreatment with NG before arterial drug infusion confirmed this result (18).

Innovations in photodynamic therapy (PDT)

For fluorescent tumor imaging and PDT, rational design of photosensitizers (PSs) and light irradiation are needed. PDT has been known for more than a century, but PDT is not very popular in clinical practice. PDT requires good molecular probes or PSs. Conventional PSs such as Laserphyrin[®] have low MW and do not demonstrate the typical EPR effect. They were excreted into bile or feces very quickly (>95%), shortly after intravenous injection; only a small fraction, far less than 1%, was found in tumors at 24 h. That is, low-MW PSs are disseminated throughout the body, but more are found

in the liver, kidney, and spleen (20). Polymeric drugs, however, including plasma proteins and other biocompatible polymers, localize more selectively in solid tumors because of the EPR effect (1,6-8).




Figure 1. The EPR effect of polymer (HPMA)-conjugated zinc protoporphyrin (ZnPP) (a), free ZnPP (a'). It is also seen with bovine serum albumin (BSA)-conjugated rhodamine (b), and free tetramethyl rhodamine (b') in tumor-bearing mice. Macromolecules, both HPMA Zn-PP and BSA-rhodamine with apparent MWs about 500 kDa and 70 kDa, respectively, selectively accumulated in tumors, because of the EPR effect, as shown by the *in vivo* fluorescent imaging system; on the contrary both free ZnPP and free rhodamine, with MWs less than 1000 Da, showed little tumor uptake. Adapted from (6) with permission.

In addition to the spectroscopic system used in traditional PDT, He/Ne and YAG lasers are utilized, which do not emit light at the protoporphyrin wavelength (about 430 nm) but instead emit light with a wavelength of 633 or 532 nm. Excitation of many of current PSs thus produces a very low quantum yield. Our zinc protoporphyrin (the PS)-conjugated polymer caused impressive regression of chemically induced

autochthonous breast cancer in rats, and this regression could be seen, via either blue fluorescent light (emission maximum 410–440 nm) or xenon-based endoscopic light, from the body surface.

Conclusion

Macromolecular drugs, or nanomedicines, to treat cancer are now being developed. Many advantages exist for these drugs, not only for tumor targeting based on the EPR effect but also for the potential to control metastasis via lymphotropism, and elucidation of these clinical treatments is warranted (10,11). The unique tumor environment, such as low pH, that can lead to release of drugs from carrier particles or polymer chains can be exploited for such nanomedicines, but not simple low-MW compounds. The EPR effect will be enhanced by using non-toxic, inexpensive vascular mediators, which will be of great clinical benefit. PDT should also be investigated with this concept in mind, to stimulate future innovations.

Executive Summary

- EPR is the first most critical step at vascular level to achieve tumor selective drug delivery.
- Advantage of nanomedicine is a capacity to remain high in plasma concentration and thus utilization of the EPR effect.

- EPR-based tumor selective delivery can be increased further by common vascular mediator like nitroglycerin and others.
- Polymer-conjugated drug can be easily designed to respond to the tumor environment and release active drug in tumor.
- Many common vascular mediators operate in cancer and inflammation that affect vascular leakiness.
- Lymphotropic, and thus antimetastatic property, and oral formulation, may be possible by lipid formulation of the polymer conjugated low MW drugs.

(1,718 words)

1. Maeda H, Konno T. Metamorphosis of neocarzinostatin to SMANCS: chemistry, biology, pharmacology, and clinical effect of the first prototype anticancer polymer therapeutic. In: *Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug*. Maeda H, Edo K, Ishida N. (Eds.), Springer-Verlag, Tokyo, Japan, 227-267 (1997).
2. Maeda H. Microbial proteinases and pathogenesis of infection. In: *The Encyclopedia of Molecular Medicine (Volume 4)*. Creighton TE (Ed.), John Wiley & Sons, Inc., NY, USA, 2663-2668 (2002).
3. Oda T, Akaike T, Hamamoto T *et al.* Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. *Science* 244, 974-976 (1989).
4. Akaike T, Noguchi Y, Ijiri S, *et al.* Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. *Proc. Natl. Acad. Sci. USA* 93, 2448-2453 (1996).
5. Matsumura Y, Maruo K, Kimura M, *et al.* Kinin-generating cascade in advanced cancer patients and *in vitro* study. *Jpn. J. Cancer Res.* 82, 732-741 (1991).
6. Maeda H. The link between infection and cancer. Tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. *Cancer Sci.* 104, 779-789 (2013).
7. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. *Adv. Drug Deliv. Rev.* 6, 181-202 (1991).

8. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. *Cancer Res.* 46, 6387-6392 (1986).
9. Maeda H, Takeshita J, Yamashita A. Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin. *Eur. J. Cancer* 16, 723-731 (1980).
10. Maeda H, Takeshita J, Kanamaru R, *et al.* Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent- and water-soluble polymer-conjugated protein. *Gann* 70, 601-606 (1979).
11. Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. *Crit. Rev. Ther. Drug Carrier Syst.* 6, 193-210 (1989).
12. Daruwalla J, Nikfarjam M, Greish K, *et al.* In vitro and in vivo evaluation of tumor targeting SMA-pirarubicin micelles: survival improvement and inhibition of liver metastases. *Cancer Sci.* 101, 1866-1874 (2010).
13. Ohtsuka N, Konno T, Miyauchi Y, *et al.* Anticancer effects of arterial administration of the anticancer agent SMANCS with Lipiodol on metastatic lymph nodes. *Cancer* 59, 1560-1565 (1987).
14. Iwai K, Maeda H, Konno T. Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. *Cancer Res.* 44, 2115-2121 (1984).
15. Konno T, Maeda H, Iwai K, *et al.* Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. *Cancer* 54, 2367-2374 (1984).
16. Nagamitsu A, Greish K, Maeda H. Elevating blood pressure as a strategy to increase tumor targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. *Jpn. J. Clin. Oncol.* 39, 756-766 (2009).
17. Oka K, Miyamoto Y, Matsumura Y, *et al.* Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, smancs, in an oily formulation. *Pharmaceut. Res.* 7, 852-855 (1990).
18. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. *J. Control. Release* 164, 138-144 (2012).
19. Yasuda H, Yamaya M, Nakayama K, *et al.* Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. *J. Clin. Oncol.* 24, 688-694 (2006).
20. Gomer CJ, Ferrario A. Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model. *Cancer Res.* 50, 3985-3990 (1990).

Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls

Authors' Names

Hideaki Nakamura^{1,2}, Fang Jun^{1,2}, and Hiroshi Maeda¹

Affiliations

¹Institute for Drug Delivery Science, and ²Laboratory of Microbiology and Oncology, Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto, 860-0082, Japan

Areas covered

Based on the EPR effect, the mechanism for more universal tumor delivery using macromolecular drugs, to cover wider tumor-types than single molecular target, is discussed. Unique properties of solid tumor vasculature in the tumor tissue are discussed, especially leakiness of the blood vessels and factors involved and impaired clearance of macromolecular drugs from the tumor interstitium via the lymphatic system. Criteria of such macromolecular drugs or nanomedicines for effective tumor accumulation is commented. Importance of long plasma retention time of such drugs, and a need of release of active principles from nanoparticles at target site, are also commented. Methods to augment the EPR effect and tumor delivery (2-3 times), and its application to the photodynamic therapy (PDT) are also commented.

Keywords

enhanced permeability and retention (EPR) effect of solid tumor, tumor selective drug delivery, macromolecular drug, barriers to tumor delivery, application of EPR effect to PDT, nanomedicine, augmentation of EPR effect

Introduction

The door to the antitumor chemotherapy opened with the first publication of the report that nitrogen mustard gas, a classic chemical warfare agent, markedly suppressed lymphoid tumors. Since 1948, various anticancer therapeutic agents have been developed [1, 2]. Most such drugs were cytotoxic and exerted a therapeutic effect by

1
2
3
4
5 inhibiting DNA synthesis or various enzyme functions, followed by apoptosis or necrosis.
6 However, these cytotoxic mechanisms were not selective for cancer cells. They also
7 affected normal cells, and therefore whole body distribution of such cytotoxic agents
8 caused many serious adverse effects. Such non-selective toxicity to normal tissues and
9 vital organs such as bone marrow led to dose-limiting toxicity, so maximal drug dosages
10 were restricted, which resulted in inadequate therapeutic outcomes. Developing
11 tumor-selective therapies has therefore been a goal of cancer researchers. Surgical
12 excision and radiation therapy have provided more direct elimination of, or damage to,
13 tumor tissues. However, the efficacy of these therapeutic modalities was mainly limited
14 to primary tumors or to clearly visible or detectable tumors.
15
16
17
18
19

20 Malignant tumors possess the inherent property of metastasis; that is, primary
21 tumor cells spread to distant sites in the body and form metastatic tumor nodules. The
22 hallmark event in this regard is lymph node metastasis. After tumor cells metastasize
23 to distant sites, they become extremely difficult to find, and thus eradicating cancer
24 completely by surgical removal or radiation therapy alone is a formidable task. Under
25 such circumstances, chemotherapy offers hope for treating metastatic tumors, because
26 drugs can be delivered to the entire body via the systemic circulation. However,
27 indiscriminate distribution of most, if not all, low-molecular-weight (low-MW) drugs
28 causes serious systemic adverse effects, as just mentioned. To achieve the desired
29 tumor-selective delivery of chemotherapeutic agents, drugs must distinguish tumor
30 tissues from normal tissues. This concept of selective toxicity was proposed at the end
31 of 19th century by Paul Ehrlich. Although selective toxicity in bacterial chemotherapy
32 was successful with the use of sulfonamide and penicillin [3], no drug successfully
33 achieved such universal selectivity for solid tumors.
34
35
36
37
38
39

40 Before 1979, when we developed the first polymeric conjugate drug SMANCS
41 (poly(styrene-co-maleic acid)-conjugated neocarzinostatin) [4], no anticancer
42 macromolecular drugs, which can utilize the pathophysiological characteristics of tumor
43 blood vessels for tumor-selective toxicity, existed. Classic cytotoxic anticancer drugs
44 affect rapidly dividing cancer cells more than non-dividing normal cells, which occur in
45 most normal tissues, by inhibiting DNA synthesis [1].
46
47
48

49 Furthermore, classic drug-screening models most often utilized ascitic
50 leukemia models such as murine L1210 or P388, in which tumor cells propagated in the
51 peritoneal cavity (i.e. intraperitoneally [i.p.]), and candidate drugs were therefore
52 administered i.p. This system involved little pharmacokinetic consideration or
53 utilization of the vascular physiology of solid tumors.
54
55

56 The more recent trend in anticancer drug development, with so-called
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

molecular target drugs and antibody drugs, will in theory produce a greater tumor-selective effect by utilizing unique enzymes in tumors such as protein kinase inhibitors, by inhibiting growth factors (EGF [endothelial growth factor] or VEGF [vascular endothelial growth factor]), or by utilizing receptor antagonists of these factors [5]. According to this concept, molecular target drugs should be safer and highly selective for tumors and will not affect normal tissues and organs. Imatinib, the most successful example, is used to treat chronic myelogenous leukemia, in which the abnormal fusion protein (BCR-ABL) is the key protein and imatinib inhibits the function of the fusion protein kinase [6, 7]. Imatinib became a first-line drug and improved the 10-year survival rate in patients with chronic myelogenous leukemia, from 20% to 85% [8].

Furthermore, antibody drugs, most of them being monoclonal antibodies (mAbs) targeting VEGF and growth factor receptors on the tumor cell surface, have been used to treat colon, lung, and breast cancers [5, 9, 10]. Contrary to initial expectations, the adverse effects of molecular target drugs, although occurring with low frequency, are not negligible and may lead to fetalities [11]. In a number of cases, mAb-based molecular target drugs, such as mAbs targeting CTLA-4 (cytotoxic T-lymphocyte antigen 4) or PD-1 (programmed cell death 1), had a significant antitumor effect [12, 13]. In most cases, however, the therapeutic effect was not as marked as that of imatinib and the cost of the drugs did not merit their use [8]; this cost issue is a frequent concern of many specialists and agencies. These discrepancies between the theoretical expectation and clinical results may be due to genetic diversity or heterogeneity and polyclonal properties of tumors in clinical settings, as seen via genomic analyses of many solid tumors observed in clinics [14-16].

1. The enhanced permeability and retention (EPR) effect—the first step in tumor-selective drug delivery

The EPR effect is observed in most solid tumors, primarily with biocompatible macromolecules when they are administered intravenously (i.v.). An EPR effect-mediated drug accumulation was observed with various macromolecules such as lipid particles, proteins, synthetic polymers, liposomes, and micelles, with molecular sizes of more than 40 kDa, or 7-8 nm [17]. Therefore, tumor-selective delivery or selective toxicity of antitumor drugs can be achieved by conjugating or encapsulating low-MW antitumor drugs to macromolecular vehicles (proteins, liposomes, polymers, and micelles) (Figure 1). The EPR phenomenon occurs at physiological or tissue levels, not at cellular or subcellular levels. Thus, we can utilize this phenomenon for a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

universal method to deliver drugs to various solid tumors and obtain selective toxicity [18]. This unique property of the EPR effect, namely, an elevated vascular permeability and retention of drugs in tumor tissues, derives primarily from three components: (i) defective vascular architecture (large gaps between endothelial cell linings and other defect in vascular architecture, (ii) excessive production of vascular mediators (e.g. bradykinin and nitric oxide [NO]), and (iii) impaired lymphatic recovery from the tumor interstitium.

1.1 Factors enhancing vascular permeability

A phenomenon similar to the EPR effect occurs in infected and inflamed tissues: various inflammatory cytokines and chemokines are secreted, thereby increasing vascular permeability and leading to edema, fever, and/or pain. The leaky nature of the tumor vasculature becomes more apparent with most biocompatible plasma proteins, such as albumin (67 kDa), transferrin (90 kDa), and immunoglobulin G (IgG) (170 kDa). The increased vascular permeability in tumor tissue is caused by architectural defects and overproduction of vascular mediators, most of which are proinflammatory effectors. Vascular permeability factors overproduced at or near tumor tissues include bradykinin, NO, prostaglandins, VEGF, tumor necrosis factor- α (TNF- α), carbon monoxide (CO) by heme oxygenase (HO)-1, and others [19, 20]. Many reports on this issue have been published [16, 19, 21, 22].

These vascular mediators facilitate the opening of vascular endothelial cell-cell gaps in normal blood vessels as well, which allows extravasation of macromolecules or nanoparticles of more than 10 nm, including viruses and even bacteria with sizes in the micrometer range (Fang et al., unpublished). Intercellular gap openings in the tumor vasculature may range from 20 nm to 2 μ m or larger [23, 24]. This situation is great contrast to endothelial gaps seen in normal vasculature (<5 nm).

1.2 Cause of longer retention of macromolecules in tumor tissue and impaired lymphatic clearance

The lymphatic network exists throughout the body and acts as a drainage system for components of interstitial tissue fluid, particularly lipid particles and plasma proteins that extravasate from the blood circulation. However, we observed impaired lymphatic function in tumor tissues, which contributes to retention of such macromolecules in tumors [21, 25]. The issue of lymphatic clearance in tumor tissues differs somewhat from that in inflamed tissues. That is, extravasated proteins and lipid particles in inflamed tissues are cleared by the lymphatic system within about a week. Clearance

1
2
3
4
5 in tumor tissues, however, is extremely slow or almost non-existent (see reports on
6 SMANCS/Lipiodol in human hepatoma [26-29]). Lipids and macromolecules in tumor
7 tissues can thus accumulate via a unique phenomenon in tumor tissues [16, 25, 26].
8 We found that all lipid particles and the lipid contrast agent Lipiodol were recovered
9 from the interstitium of normal tissue via the lymphatic system.

10
11
12 We also observed, however, accumulation of Lipiodol in tumor tissues,
13 particularly in hepatoma, but no clearance of the Lipiodol [25, 26, 29, 30]. That is, we
14 developed an arterial infusion method in which we infused lipophilic
15 polymer-conjugated SMANCS dissolved in Lipiodol, where Lipiodol used as the carrier.
16 The concentration of the drug in tumor tissue, compared with that of blood plasma level,
17 was more than 2,000 fold higher (tumor/blood). Therefore, this arterial infusion method
18 with a drug in Lipiodol, can achieved a very selective tumor-targeting [25], and our
19 therapeutic results improved markedly via this method [16, 26, 29].
20
21
22
23
24

25 26 **2. Conditions required for manifestation of the EPR effect in tumor tissues** 27 **with targeted nanomedicines**

28 An EPR effect-mediated accumulation of drugs in tumors can operate with many types
29 of macromolecular drugs; however, several criteria must be met, as described below.
30 For example, macromolecules must remain in the systemic circulation for more than
31 several hours, because the EPR effect is a time-dependent phenomenon: during
32 circulation in blood, the macromolecules gradually leak out of the blood vessels and
33 selectively into tumor tissues. To remain in the circulation for a long time, drugs must
34 possess several properties: (i) large molecular size, (ii) biocompatibility, (iii) proper
35 surface charge, and (iv) stability of macromolecular integrity.
36
37
38
39
40

41 **2.1 Molecular size**

42 We should emphasize that the EPR effect is a molecular size-dependent phenomenon
43 (i.e. >40 kDa). In general, low-MW drugs are primarily removed via renal excretion, so
44 they enter the urine, or via hepatic functions, so they appear in the bile and then the
45 feces. For the EPR effect-dependent accumulation of drugs in tumors, macromolecular
46 drugs must circulate and then gradually move into the interstitial tissue of the tumor.
47 The renal glomerular pore size is about 6 nm, so the size of the macromolecules
48 influences renal excretion to a great extent [31, 32]. The renal excretion threshold is
49 believed to be about 40 kDa, and thus hydrophilic polymeric drugs smaller than 30 kDa
50 may be rapidly excreted from the kidney, without any chance to accumulate in tumor
51 tissues. Low-MW drugs also easily pass through the normal vasculature and then
52
53
54
55
56
57
58
59
60